SLC5A2 and heart failure: Sodium-glucose cotransporter 2 (SGLT2) inhibitors recently have been shown to reduce the risk of heart failure hospitalization and cardiovascular death in patients with HFrEF.11,12 The mechanism or mechanisms underlying these benefits are uncertain, including whether SGLT2 inhibitors have a favorable effect on cardiac remodeling.